Conclusion
MM
MYELOMA
These findings demonstrate that anti-PD-L1 therapy with Atezo (as monotherapy and in combination) is safe and has the expected immunologic activity in MM patients. Integrated SNF analysis of high-dimensional immunophenotyping data demonstrated that patient selection based on clinical criteria had a significant impact on the immunologic state of the TME at baseline. Novel correlations with clinical outcome suggest that T-cell associated factors may predict response to treatment. With the rapid introduction of novel immune therapies in MM including CAR-T cells and bispecific antibodies, addressing mechanisms of immune escape is even more critical. Therefore, we believe that the safety and efficacy data reported here support further investigation of PD-L1 checkpoint inhibition combinations in myeloma. This rational immune-oncology approach may enhance understanding of myeloma-TME biology and promote biomarker-driven treatment.